1M+ revenue German oncology company for sale

Privately owned pharmaceutical company, 专门从事肿瘤学领域 (仿制药, 肠胃外的), IV期临床研究在私营部门市场上表现强劲. 5 积极销售的产品, 4 products to be launched. The business model is marketing and selling to oncologist in Germany.
Production is outsourced to well-known and reliable CMOs. Supply chain is secured. Licensor agreed to extend territory to pan-Europe, if requested. Revenue 1M+, profitable, EBITDA 15%, 5 employees.
1,3 M Euro EBITDA Dermatology company in Italy for sale

Privately owned Italian pharmaceutical company founded in 2000, focused in dermatology field. Strong brands are amongst the most recommended by dermatologists in Italy. Product range of Cosmeceuticals, Medical Devices and Food Supplements for treatment of several dermatological pathologies. The Company has a team of 8 employees: a highly educated professional staff with substantial experience and are promoted by highly skilled 27 reps sales force (exclusive agents). Financials 2016 – 5.35M Euro revenue, 1.3M Euro EBITDA; 2017B 6.0M Euro revenue, 1.4M Euro EBITDA; 24% EBITDA margin, 15% annual revenue growth, No debts. Shareholders are willing to sell 100% of the shares
3,5 M Euro revenue Italian CMO for sale

Oral solids and liquids, pharmaceutical and Medical devices, 35 employees, 3.5 M Euro revenue, EBITDA <0
200 K Euro revenue brand divestment in Germany

MA and brand in Germany in Hormone replacement therapy (HRT) for the relief of complaints during or after menopause as well as osteoporosis prevention. For sale is a longterm established and marketed product, German MA granted no limits, no expiration + Trademark. Without promotion activities stable annual revenues of 200.000 欧元. Product is in the reimbursement list. Possibility to co-operate with existing CMO or own production to be discussed. Stock is available for a smooth business transaction.
1M Euro revenue Hospital businesses in Spain for sale

The company registers and distributes high quality pharmaceutical products (contrast agents for X-ray, CT and MRI) in an exclusive agreement; it holds own MAHs and Brands for the Spanish market and distributes these products to the hospitals. The company is about to launch a new generation of radiological products in the Spanish market, as well as registering and commercializing new oncology diagnostic products 10 people, 7 of which are sales force covering different regions. Annual revenue app. 1 M Euro, gross margin approximately 55%.
13M+ USD growing profitable Pharmaceutical Company for sale in Brazil

Privately owned pharmaceutical company based in Brazil that produces and commercializes pharmaceutical products with its own brands. ANVISA approved plant, where it has registered 31 products. Sales: Liquids 62%, Solids 25%, Semisolids 13%; Distribution of Sales: OTC – 37%, Phytopharmaceuticals – 29%, Generic drugs – 17%, 42.500 m2 of industrial space recently acquired and approved by ANVISA for industrial use. Regional Tax Incentives: reduction of 75% of Income Tax for 10 年份, between other fiscal incentives for industrials. Revenues 2016: 43.5 M Reals (13M+ USD), EBITDA 2016: 4.7 M Reals (1.4 M USD), 330 Employees: Sales CAGR 2006-2016 12%
25M+ Euro revenue profitable European company for sale

Fast growing pharmaceutical sales & marketing group with ca. 20 employees, product portfolio of 150 high quality Rx and OTC products (mostly EU CTD dossiers produced in EU GMP plants), therapeutic categoriescentral nervous system, cardiovasculars, 肿瘤科, gastroenterology, respiratory, pain management, 骨质疏松, allergology, infectiology, around 600 MAs already granted globally, additional 50 MAs pending under ongoing regulatory procedures, main operations in Germany, also in EU markets: 英国, 丹麦, 波兰, 荷兰, 葡萄牙, 意大利, 西班牙, other and international sales in 33 国家. Cooperating with selected top-notch manufacturers in Europe and Asia. EU GMP and Wholesaler License, EU Import License, no real estate, no production plant, no bank loans, no pension liabilities. 25M Euro revenue; 1.8M Euro EBITDA for 2017 with a carefully selected product portfolio.
8M Euro revenue profitable pharma company for Sale in West Europe

The company manages the marketing, selling and distribution of pharmaceutical/medical supplies and devices in the several markets of North Western Europe. 该 8 million euro business growing and profitable business. Pharmaceuticals/devices currently represented include injectables, infusions, tablets and devices addressing the areas of pain management, womens reproductive health, fungal infection and thyroid conditions. Besides managing their own products, the company also represents international organisations that do have not have a local marketing, sales and distribution representative. Company do not have own production plant.
EU GMP running injectable manufacturing plant in Spain for sale

Profitable and growing CDMO (contract development & manufacturing organization) is available for sale. 15 employees, own land (5.000 sq.m), 建造 (2.000 sq.m.), 设备, no debts. Manufacturing in glass container, PP container, PP bags, irrigation solutions. Products New 3 ophthalmology lines (mono-dose and multi-dose) EU GMP approval expected within 2017.
18+ M Euro profitable growing ANVISA distributor in Brazil for sale

Based in So Paulo, Specialised in the field of otorhinolaryngology and orthopaedic, represents two of the largest global suppliers with exclusivity in the Brazilian market. Clients of the company are mainly private (95%) with only 5% of government buyers. Its strategic position in the Brazilian market is coupled by a solid image in the medical profession and clients with unblemished reputation and tradition for over 30 年份. Growing annual revenue: 2016 – 14.7 M Euro, EBITDA (26%) 3.8 M Euro, 90 employees, no debts, net cash 1.5 M Euro. Motivation for sale: evaluating other business scenarios.
3.7+ USD profitable growing PICS GMP plant in Indonesia for sale

建立在 1984, PICS GMP running (last approval in 2016) manufacturing plant in Jakarta, 印度尼西亚 5,167 sq.m. of land, 3,184 sq.m. of building and new machines installed in 2014 和 2015.
3 business divisions: Generics, Specialty and Herbal. Total of 164 SKUs.
Market leader for Anti-inflammatory product covers 60+% of anti inflammatory products in Indonesia.Products are distributed to cities in 31 provinces in Indonesia through 23 distributors, such as Kimia Farma, Tempo, and Mensa Bina Sukses. Parcipating in government tenders. Production capacity 1 M tablets / day will be increased with the new machines. 50% is used capacity at the moment. 135 employees, Assets 11.4 M USD, Annual revenue 3.7 M USD, EBITDA 22%,
Seeking to sell pharmaceutical company or brand divestment ?

On behalf of our clients we are looking to acquire pharmaceutical business in USA, 一世, MENA, 亚洲, LATAM. We are interested in brand divestments, pharmaceutical business with/without factories for sale. Please e-mail head_office@nbscience.com

分类: 干细胞治疗